Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
ALEMBIC TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-23 |
TEVA PHARMA Dec-13 |
ALEMBIC/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 87 | 3,480 | - | |
Low | Rs | 56 | 3,023 | - | |
Sales per share (Unadj.) | Rs | 5.0 | 1,997.4 | - | |
Earnings per share (Unadj.) | Rs | 3.1 | 124.8 | - | |
Cash flow per share (Unadj.) | Rs | 3.4 | 286.2 | - | |
Dividends per share (Unadj.) | Rs | 2.20 | 109.23 | - | |
Avg Dividend yield | % | 3.1 | 3.4 | 91.9% | |
Book value per share (Unadj.) | Rs | 80.9 | 2,218.7 | - | |
Shares outstanding (eoy) | m | 256.78 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 14.4 | 1.6 | 883.3% | |
Avg P/E ratio | x | 22.7 | 26.1 | 87.1% | |
P/CF ratio (eoy) | x | 21.0 | 11.4 | 184.4% | |
Price / Book Value ratio | x | 0.9 | 1.5 | 60.1% | |
Dividend payout | % | 70.1 | 87.5 | 80.0% | |
Avg Mkt Cap | Rs m | 18,298 | 2,757,543 | 0.7% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 240 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,685.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,354.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,272 | 1,693,781 | 0.1% | |
Other income | Rs m | 643 | 0 | - | |
Total revenues | Rs m | 1,915 | 1,693,781 | 0.1% | |
Gross profit | Rs m | 297 | 463,843 | 0.1% | |
Depreciation | Rs m | 67 | 136,910 | 0.0% | |
Interest | Rs m | 5 | 33,269 | 0.0% | |
Profit before tax | Rs m | 868 | 293,664 | 0.3% | |
Minority Interest | Rs m | 0 | 1,334 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,775 | -0.0% | |
Tax | Rs m | 62 | -3,585 | -1.7% | |
Profit after tax | Rs m | 806 | 105,809 | 0.8% | |
Gross profit margin | % | 23.4 | 27.4 | 85.3% | |
Effective tax rate | % | 7.1 | -1.2 | -583.1% | |
Net profit margin | % | 63.4 | 6.2 | 1,014.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,721 | 1,143,974 | 0.2% | |
Current liabilities | Rs m | 838 | 997,642 | 0.1% | |
Net working cap to sales | % | 69.4 | 8.6 | 803.5% | |
Current ratio | x | 2.1 | 1.1 | 179.1% | |
Inventory Days | Days | 5,038 | 91 | 5,549.4% | |
Debtors Days | Days | 673 | 96 | 701.4% | |
Net fixed assets | Rs m | 20,324 | 553,226 | 3.7% | |
Share capital | Rs m | 514 | 4,169 | 12.3% | |
Net worth | Rs m | 20,780 | 1,881,470 | 1.1% | |
Long term debt | Rs m | 0 | 866,068 | 0.0% | |
Total assets | Rs m | 22,046 | 3,870,833 | 0.6% | |
Interest coverage | x | 187.7 | 9.8 | 1,909.6% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.1 | 0.4 | 13.2% | |
Return on assets | % | 3.7 | 3.6 | 102.4% | |
Return on equity | % | 3.9 | 5.6 | 69.0% | |
Return on capital | % | 4.2 | 4.9 | 85.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 389 | 269,901 | 0.1% | |
From Investments | Rs m | 73 | -95,637 | -0.1% | |
From Financial Activity | Rs m | -464 | -323,765 | 0.1% | |
Net Cashflow | Rs m | -2 | -149,500 | 0.0% |
Compare ALEMBIC With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare ALEMBIC With: BDH INDUS. SEQUENT SCIENTIFIC SHILPA MEDICARE ASTRAZENECA PHARMA CAPLIN POINT
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.